Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications
Tóm tắt
Từ khóa
Tài liệu tham khảo
Neels, 2004, Therapeutic drug monitoring of old and newer anti-epileptic drugs, Clin. Chem. Lab. Med., 42, 1228, 10.1515/CCLM.2004.245
Patsalos, 2008, Antiepileptic drugs—Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies, Epilepsia, 49, 1239, 10.1111/j.1528-1167.2008.01561.x
Eichelbaum, 1981, A prospective randomized trial on the effect of monitoring plasma anticonvulsant levels in epilepsy, J. Neurol., 224, 193, 10.1007/BF00313281
Januzzi, 2000, A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy, Epilepsia, 41, 222, 10.1111/j.1528-1157.2000.tb00144.x
Liu, 1999, Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants, Clin. Pharmacokinet., 36, 453, 10.2165/00003088-199936060-00006
Berry, 2003, The absorption of gabapentin following high dose escalation, Seizure, 12, 28, 10.1016/S1059131102001425
Tsiropoulos, 2000, Saliva and serum concentration of lamotrigine in patients with epilepsy, Ther. Drug. Monit., 22, 517, 10.1097/00007691-200010000-00003
Mecarelli, 2007, Saliva and serum levetiracetam concentrations in patients with epilepsy, Ther. Drug. Monit., 29, 313, 10.1097/FTD.0b013e3180683d55
Miles, 2004, Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD), Ther. Drug. Monit., 26, 300, 10.1097/00007691-200406000-00014
Miles, 2003, Topiramate concentration in saliva: An alternative to serum monitoring, Pediatr. Neurol., 29, 143, 10.1016/S0887-8994(03)00048-1
Kumagai, 1993, Concentrations of zonisamide in serum, free fraction, mixed saliva and cerebrospinal fluid in epileptic children treated with monotherapy, Jpn. J. Psychiatry Neurol., 47, 291
Jones, 2005, Stability of salivary concentrations of the newer antiepileptic drugs in the postal system, Ther. Drug Monit., 27, 576, 10.1097/01.ftd.0000171869.56817.ae
Bialer, 2005, The pharmacokinetics and interactions of new antiepileptic drugs: An overview, Ther. Drug Monit., 27, 722, 10.1097/01.ftd.0000179854.16846.67
Perucca, 2006, Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age, Clin. Pharmacokinet., 45, 351, 10.2165/00003088-200645040-00002
Perucca, 1996, The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine, Clin. Pharmacokinet., 31, 29, 10.2165/00003088-199631010-00003
Tien, 2006, Nuclear receptors CAR and PXR in the regulation of hepatic metabolism, Xenobiotica, 36, 1152, 10.1080/00498250600861827
Zhang, 2008, PXR: A xenobiotic receptor of diverse function implicated in pharmacogenetics, Pharmacogenomics, 9, 1695, 10.2217/14622416.9.11.1695
Lacerda, 2006, Optimizing therapy of seizures in patients with renal or hepatic dysfunction, Neurology, 67, S28, 10.1212/WNL.67.12_suppl_4.S28
Pitlick, 1977, Time-dependent kinetics I: Exponential autoinduction of carbamazepine in monkeys, J. Pharm. Sci., 66, 647, 10.1002/jps.2600660511
Dasgupta, 2007, Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management, Clin. Chim. Acta, 377, 1, 10.1016/j.cca.2006.08.026
LaRoche, 2004, The new antiepileptic drugs: Clinical applications, JAMA, 291, 615, 10.1001/jama.291.5.615
2008, Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy, CNS Drugs, 22, 27, 10.2165/00023210-200822010-00003
Perucca, 2000, Is there a role for therapeutic drug monitoring of new anticonvulsants?, Clin. Pharmacokinet., 38, 191, 10.2165/00003088-200038030-00001
Johannessen, 2006, Pharmacokinetic variability of newer epileptic drugs?, Clin. Pharmacokinet., 45, 1061, 10.2165/00003088-200645110-00002
Ambrosio, 2001, Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels, Biochem. Pharmacol., 61, 1271, 10.1016/S0006-2952(01)00584-6
Maia, 2005, Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093), Drugs R D, 6, 201, 10.2165/00126839-200506040-00002
Almeida, 2005, Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects, J. Clin. Pharmacol., 45, 1062, 10.1177/0091270005279364
Almeida, 2010, Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects, Acta Neurol. Scand., 121, 257, 10.1111/j.1600-0404.2009.01233.x
Bialer, 2009, Progress report on new antiepileptic drugs: A summary of the ninth eilat conference (EILAT IX), Epilepsy Res., 83, 1, 10.1016/j.eplepsyres.2008.09.005
Almeida, 2008, Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment, Eur. J. Clin. Pharmacol., 64, 267, 10.1007/s00228-007-0414-1
Maia, 2008, Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate, Int. J. Clin. Pharmacol. Ther., 46, 119, 10.5414/CPP46119
Alves, 2007, Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma, Biomed. Chromatogr., 21, 1127, 10.1002/bmc.858
Popova, 2007, Oxcarbazepine in the treatment of bipolar and schizoaffective disorders, Expert Rev. Neurother., 7, 617, 10.1586/14737175.7.6.617
Wagner, 1991, Discontinuation of phenytoin and carbamazepine in patients receiving felbamate, Epilepsia, 32, 398, 10.1111/j.1528-1157.1991.tb04669.x
Ramsay, 1991, Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy, Epilepsy Res., 10, 191, 10.1016/0920-1211(91)90012-5
May, 2003, Clinical pharmacokinetics of oxcarbazepine, Clin. Pharmacokinet., 42, 1023, 10.2165/00003088-200342120-00002
Perucca, 2008, Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy, Epilepsia, 49, 1123, 10.1111/j.1528-1167.2008.01665.x
So, 1995, Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs, Epilepsy Res., 22, 221, 10.1016/0920-1211(95)00048-8
Britzi, 2005, Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine, Epilepsia, 46, 378, 10.1111/j.0013-9580.2005.55204.x
Faught, 1993, Felbamate monotherapy for partial-onset seizures: An active-controlled trial, Neurology, 43, 688, 10.1212/WNL.43.4.688
Sachdeo, 1992, Felbamate monotherapy: Controlled trial in patients with partial onset seizures, Ann. Neurol., 32, 386, 10.1002/ana.410320313
Lindberger, 2003, Serum concentrations and effects of gabapentin and vigabatrin: Observations from a dose titration study, Ther. Drug Monit., 25, 457, 10.1097/00007691-200308000-00007
Kellinghaus, 2009, Lacosamide as treatment for partial epilepsy: Mechanisms of action, pharmacology, effects, and safety, Ther. Clin. Risk Manag., 5, 757, 10.2147/TCRM.S5189
Bartoli, 1997, The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: A prospective study with preliminary assessments of correlations with clinical response, Ther. Drug Monit., 19, 252, 10.1097/00007691-199706000-00002
Leppik, 2002, Effective levetiracetam doses and serum concentrations: Age effects, Epilepsia, 43, 240
Friis, 1993, Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment, Acta Neurol. Scand., 87, 224, 10.1111/j.1600-0404.1993.tb04106.x
Farwell, 1993, Stiripentol in atypical absence seizures in children: An open trial, Epilepsia, 34, 305, 10.1111/j.1528-1157.1993.tb02416.x
Uthman, 1998, Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial, Arch. Neurol., 55, 56, 10.1001/archneur.55.1.56
Johannessen, 2003, Therapeutic drug monitoring of the newer antiepileptic drugs, Ther. Drug Monit., 25, 347, 10.1097/00007691-200306000-00016
Mimaki, 1998, Clinical pharmacology and therapeutic drug monitoring of zonisamide, Ther. Drug Monit., 20, 593, 10.1097/00007691-199812000-00001
Pellock, 2006, Felbamate: Consensus of current clinical experience, Epilepsy Res., 71, 89, 10.1016/j.eplepsyres.2006.06.020
Thompson, 1999, Quantification in patient urine samples of felbamate and three metabolites: Acid carbamate and two mercapturic acids, Epilepsia, 40, 769, 10.1111/j.1528-1157.1999.tb00777.x
Shumaker, 1990, Evaluation of the elimination of (14C) felbamate in healthy men, Epilepsia, 31, 642
Sachdeo, 1993, Steady-state pharmacokinetics and dose-proportionality of felbamate after oral administration of 1200, 2400, and 3600 mg/day of felbamate, Epilepsia, 34, 80
Ward, 1991, Felbamate steady-state pharmacokinetics during co-administration of valproate, Epilepsia, 32, 8
Annesley, 1994, Determination of felbamate in human serum by high-performance liquid chromatography, Ther. Drug Monit., 16, 419, 10.1097/00007691-199408000-00014
Behnke, 1997, Determination of felbamate concentration in pediatric samples by high-performance liquid chromatography, Ther. Drug Monit., 19, 301, 10.1097/00007691-199706000-00010
Poquette, 1995, Isothermal gas chromatographic method for the rapid determination of felbamate concentration in human serum, Ther. Drug Monit., 17, 168, 10.1097/00007691-199504000-00011
Shihabi, 1994, Felbamate measured in serum by two methods: HPLC and capillary electrophoresis, Clin. Chem., 40, 1904, 10.1093/clinchem/40.10.1904
Vollmer, 1988, Pharmacokinetics and metabolism of gabapentin in rat, dog and man, Arzneimittelforschung, 36, 830
Gidal, 1998, Gabapentin bioavailability: Effect of dose and frequency of administration in adult patients with epilepsy, Epilepsy Res., 31, 91, 10.1016/S0920-1211(98)00020-5
Wong, 1995, Disposition of gabapentin in anuric subjects on hemodialysis, J. Clin. Pharmacol., 35, 622, 10.1002/j.1552-4604.1995.tb05020.x
Armijo, 2004, Association between patient age and gabapentin serum concentration-to-dose ratio: A preliminary multivariate analysis, Ther. Drug Monit., 26, 633, 10.1097/00007691-200412000-00008
Sivenius, 1991, A double-blind study of gabapentin in the treatment of partial seizures, Epilepsia, 32, 539, 10.1111/j.1528-1157.1991.tb04689.x
Bahrami, 2006, Sensitive high-performance liquid chromatographic quantitation of gabapentin in human serum using liquid-liquid extraction and pre-column derivatization with 9-fluorenylmethyl chloroformate, J. Chromatogr. B, 835, 123, 10.1016/j.jchromb.2006.03.011
Juenke, 2003, Procedure for the monitoring of gabapentin with 2,4,6-trinitrobenzene sulfonic acid derivatization followed by HPLC with ultraviolet detection, Clin. Chem., 49, 1198, 10.1373/49.7.1198
Ifa, 2001, Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study, J. Mass Spectrom., 36, 188, 10.1002/jms.120
Borrey, 2005, Quantitative determination of vigabatrin and gabapentin in human serum by gas chromatography-mass spectrometry, Clin. Chim. Acta, 354, 147, 10.1016/j.cccn.2004.11.023
Gambelunghe, 2005, Gas chromatography-tandem mass spectrometry analysis of gabapentin in serum, Biomed. Chromatogr., 19, 63, 10.1002/bmc.417
Curia, 2009, Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders, CNS Drugs, 23, 555, 10.2165/00023210-200923070-00002
Chung, 2010, Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial, Epilepsia, 51, 958, 10.1111/j.1528-1167.2009.02496.x
Biton, 2007, Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures, Epilepsia, 48, 1308, 10.1111/j.1528-1167.2007.01188.x
Patsalos, 2010, Drug interactions involving the new second- and third-generation antiepileptic drugs, Expert Rev. Neurother., 10, 119, 10.1586/ern.09.136
Beydoun, 2009, Lacosamide: Pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures, Expert Rev. Neurother., 9, 33, 10.1586/14737175.9.1.33
Gidal, 1999, Vigabatrin: A novel therapy for seizure disorders, Ann. Pharmacother., 33, 1277, 10.1345/aph.18376
Cawello, 2010, No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers, J. Clin. Pharmacol., 50, 459, 10.1177/0091270009347675
Halford, 2009, Clinical perspectives on lacosamide, Epilepsy Curr., 9, 1, 10.1111/j.1535-7511.2008.01273.x
Sabers, 2009, Managing antiepileptic drugs during pregnancy and lactation, Curr. Opin. Neurol., 22, 157, 10.1097/WCO.0b013e32832923d7
Tomson, 2007, Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium, Clin. Pharmacokinet., 46, 209, 10.2165/00003088-200746030-00002
Incecayir, 2007, Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers, Arzneimittelforschung, 57, 517
Malone, 2006, Monitoring salivary lamotrigine concentrations, J. Clin. Neurosci., 13, 902, 10.1016/j.jocn.2005.12.037
Biton, 2006, Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy, Expert Opin. Drug Metab. Toxicol., 2, 1009, 10.1517/17425255.2.6.1009
Hussein, 1997, Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: Retrospective analysis of routine monitoring data, Br. J. Clin. Pharmacol., 43, 457, 10.1046/j.1365-2125.1997.00594.x
Reimers, 2005, Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations, Epilepsia, 46, 1414, 10.1111/j.1528-1167.2005.10105.x
Sabers, 2001, Lamotrigine plasma levels reduced by oral contraceptives, Epilepsy Res., 47, 151, 10.1016/S0920-1211(01)00305-9
Fillastre, 1993, Pharmacokinetics of lamotrigine in patients with renal impairment: Influence of haemodialysis, Drug. Exp. Clin. Res., 19, 25
Morris, 1998, Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service, Br. J. Clin. Pharmacol., 46, 547, 10.1046/j.1365-2125.1998.00835.x
Pennell, 2008, Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency, Neurology, 70, 2130, 10.1212/01.wnl.0000289511.20864.2a
Morgan, 1999, Determination of lamotrigine in human plasma by high-performance liquid chromatography, J. Chromatogr. B, 727, 113, 10.1016/S0378-4347(99)00043-2
Forssblad, 1996, Liquid chromatographic determination of plasma lamotrigine in pediatric samples, J. Pharmaceut. Biomed. Anal., 14, 755, 10.1016/0731-7085(95)01669-4
Lower, 2007, Simultaneous determination of lamotrigine, zonisamide, and carbamazepine in human plasma by high-performance liquid chromatography, Biomed. Chromatogr., 21, 225, 10.1002/bmc.753
Biddlecombe, 1990, Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine, J. Pharmaceut. Biomed. Anal., 8, 691, 10.1016/0731-7085(90)80104-W
Westley, 2008, Seradyn quantitative microsphere system lamotrigine immunoassay on a Hitachi 911 analyzer compared with HPLC-UV, Ther. Drug Monit., 30, 634, 10.1097/FTD.0b013e31818580b3
Sailstad, 1991, Immunofluorometric assay for lamotrigine (Lamictal) in human plasma, Ther. Drug Monit., 13, 433, 10.1097/00007691-199109000-00008
Theurillat, 2002, Therapeutic drug monitoring of lamotrigine using capillary electrophoresis. Evaluation of assay performance and quality assurance over a 4-year period in the routine arena, J. Chromatogr. A, 979, 353, 10.1016/S0021-9673(02)01257-8
Zheng, 2004, Development of capillary zone electrophoresis-electrospray ionization-mass spectrometry for the determination of lamotrigine in human plasma, Electrophoresis, 25, 2033, 10.1002/elps.200305823
Watelle, 1997, Analysis of the antiepileptic phenyltriazine compound lamotrigine using gas chromatography with nitrogen phosphorus detection, Ther. Drug Monit., 19, 460, 10.1097/00007691-199708000-00016
Dasgupta, 1997, Lamotrigine analysis in plasma by gas chromatography-mass spectrometry after conversion to a tert.-butyldimethylsilyl derivative, J. Chromatogr. B, 693, 101, 10.1016/S0378-4347(97)00064-9
Beck, 2006, Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry, Ther. Drug Monit., 28, 603, 10.1097/01.ftd.0000245779.64080.30
Lee, W., Kim, J.H., Kim, H.S., Kwon, O.H., Lee, B.I., and Heo, K. (2010). Determination of lamotrigine in human serum by high-performance liquid chromatography-tandem mass spectrometry. Neurol. Sci., in press.
Pucci, 2005, Analysis of lamotrigine and its metabolites in human plasma and urine by micellar electrokinetic capillary chromatography, Electrophoresis, 26, 935, 10.1002/elps.200410208
Leppik, 2001, The place of levetiracetam in the treatment of epilepsy, Epilepsia, 42, S44, 10.1111/j.1528-1167.2001.00010.x
Lynch, 2004, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, Proc. Natl. Acad. Sci. USA., 101, 9861, 10.1073/pnas.0308208101
Fay, 2005, Oral absorption kinetics of levetiracetam: The effect of mixing with food or enteral nutrition formulas, Clin. Ther., 27, 594, 10.1016/j.clinthera.2005.05.010
Lins, 2007, Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers, Int. J. Clin. Pharmacol. Ther., 45, 47, 10.5414/CPP45047
Grim, 2003, Correlation of levetiracetam concentrations between serum and plasma, Ther. Drug Monit., 25, 61, 10.1097/00007691-200302000-00009
Patsalos, 2004, Clinical pharmacokinetics of levetiracetam, Clin. Pharmacokinet., 43, 707, 10.2165/00003088-200443110-00002
Patsalos, 2006, In situ metabolism of levetiracetam in blood of patients with epilepsy, Epilepsia, 47, 1818, 10.1111/j.1528-1167.2006.00819.x
Pucci, 2004, High-performance liquid chromatographic determination of Levetiracetam in human plasma: Comparison of different sample clean-up procedures, Biomed. Chromatogr., 18, 37, 10.1002/bmc.289
Ratnaraj, 1996, A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography, Ther. Drug Monit., 18, 154, 10.1097/00007691-199604000-00008
Giannoutsos, 2007, Drug monitoring: Simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam, J. Chromatogr. Sci., 45, 616, 10.1093/chromsci/45.9.616
Vermeij, 1994, High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction, J. Chromatogr. B, 662, 134, 10.1016/0378-4347(94)00393-9
Isoherranen, 2000, Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection, J. Chromatogr. B, 745, 325, 10.1016/S0378-4347(00)00293-0
Guo, 2007, Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry, Clin. Chim. Acta, 375, 115, 10.1016/j.cca.2006.06.022
Ivanova, 2003, Microemulsion electrokinetic chromatography applied for separation of levetiracetam from other antiepileptic drugs in polypharmacy, Electrophoresis, 24, 992, 10.1002/elps.200390143
Shihabi, 2003, Analysis of the antiepileptic drug keppra by capillary electrophoresis, J. Chromatogr. A, 1004, 9, 10.1016/S0021-9673(03)00716-7
Radtke, 2001, Pharmacokinetics of levetiracetam, Epilepsia, 42, 24, 10.1111/j.1528-1167.2001.00005.x
Larkin, 1991, Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects, Br. J. Clin. Pharmacol., 31, 65, 10.1111/j.1365-2125.1991.tb03858.x
Lloyd, 2007, Clinical pharmacology and pharmacokinetics of oxcarbazepine, Epilepsia, 35, S10
Cardot, 1995, Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state, Biopharm. Drug Dispos., 16, 603, 10.1002/bdd.2510160708
Rouan, 1994, The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites, Eur. J. Clin. Pharmacol., 47, 161, 10.1007/BF00194967
Furlanut, 2006, Acute oxcarbazepine, benazepril, and hydrochlorothiazide overdose with alcohol, Ther. Drug Monit., 28, 267, 10.1097/01.ftd.0000196660.89984.8d
Mazzucchelli, 2006, Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium, Epilepsia, 47, 504, 10.1111/j.1528-1167.2006.00459.x
Battino, 1995, Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate, Clin. Pharmacokinet., 29, 341, 10.2165/00003088-199529050-00004
Striano, 2006, Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcabazepine therapy, Epilepsy Res., 69, 170, 10.1016/j.eplepsyres.2006.01.011
Paar, 1985, Gas chromatographic assay for oxcarbazepine and its main metabolites in plasma, J. Chromatogr., 345, 67, 10.1016/0378-4347(85)80136-5
Paar, 1986, Gas chromatographic/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10,11-trans-diol, Biol. Mass Spectrom., 13, 651, 10.1002/bms.1200131203
Juenke, 2006, Drug monitoring and toxicology: A procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV, J. Chromatogr. Sci., 44, 45, 10.1093/chromsci/44.1.45
Vermeij, 2007, Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction, J. Chromatogr. B, 857, 40, 10.1016/j.jchromb.2007.06.023
Breton, 2005, Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma, J. Chromatogr. B, 828, 80, 10.1016/j.jchromb.2005.09.019
Paglia, 2007, Development and validation of a LC/MS/MS method for simultaneous quantification of oxcarbazepine and its main metabolites in human serum, J. Chromatogr. B, 860, 153, 10.1016/j.jchromb.2007.10.025
Pucci, 2003, Quantitation of oxcarbazepine and its metabolites in human plasma by micellar electrokinetic chromatography, Biomed. Chromatogr., 17, 231, 10.1002/bmc.217
Selak, 2001, Pregabalin (Pfizer), Curr. Opin. Invest. Drugs, 2, 828
Busch, 1998, Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses, Epilepsia, 39, 58
Corrigan, 2001, Metabolic disposition of pregabalin in healthy volunteers, Clin. Pharmacol. Ther., 69, P18
Randinitis, 2003, Pharmacokinetics of pregabalin in subjects with various degrees of renal functions, J. Clin. Pharmacol., 43, 277, 10.1177/0091270003251119
Bockbrader, 2000, Pregabalin pharmacokinetics and safety in health volunteers: Results from two phase I studies, Neurology, 11, 412
Berry, 2005, Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC, Ther. Drug Monit., 27, 451, 10.1097/01.ftd.0000158874.54100.1a
Nirogi, 2009, Liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry method for the quantification of pregabalin in human plasma, J. Chromatogr. B, 877, 3899, 10.1016/j.jchromb.2009.10.004
Wheless, 2010, Rufinamide: A novel broad-spectrum antiepileptic drug, Epilepsy Curr., 10, 1, 10.1111/j.1535-7511.2009.01336.x
Luszczki, 2009, Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions, Pharmacol. Rep., 61, 197, 10.1016/S1734-1140(09)70024-6
Contin, 2010, Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy, J. Chromatogr. B, 878, 461, 10.1016/j.jchromb.2009.11.039
Fisher, 2009, The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator, Neuropharmacology, 56, 190, 10.1016/j.neuropharm.2008.06.004
Levy, 1983, Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity, J. Clin. Pharmacol., 23, 523, 10.1002/j.1552-4604.1983.tb01799.x
Levy, 1984, Stiripentol kinetics in epilepsy: Nonlinearity and interactions, Clin. Pharmacol. Ther., 36, 661, 10.1038/clpt.1984.237
Tran, 1997, Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants, Clin. Pharmacol. Ther., 62, 490, 10.1016/S0009-9236(97)90044-8
Arends, 1994, Stereoselective pharmacokinetics of stiripentol: An explanation for the development of tolerance to anticonvulsant effect, Epilepsy Res., 18, 91, 10.1016/0920-1211(94)90001-9
Schapel, 1996, Tiagabine and non-convulsive status epilepticus, Seizure, 5, 153, 10.1016/S1059-1311(96)80111-7
Balslev, 2000, Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients, Eur. J. Paediatr. Neurol., 4, 169, 10.1053/ejpn.2000.0293
Kellinghaus, 2002, Tiagabine-related non-convulsive status epilepticus in partial epilepsy: Three case reports and a review of the literature, Seizure, 11, 243, 10.1053/seiz.2001.0594
Gustavson, 1995, Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses, Epilepsia, 36, 605, 10.1111/j.1528-1157.1995.tb02575.x
Patsalos, 2002, Concentration-dependent displacement of tiagabine by valproic acid, Epilepsia, 43, 143
Cato, 1998, Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine, Epilepsia, 39, 43, 10.1111/j.1528-1157.1998.tb01272.x
Lau, 1997, Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function, Epilepsia, 38, 445, 10.1111/j.1528-1157.1997.tb01734.x
Gustavson, 1997, A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures, Neurology, 48, 1032, 10.1212/WNL.48.4.1032
Williams, 2003, Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data, Epilepsia, 44, 40, 10.1046/j.1528-1157.2003.26702.x
Chollet, 1999, Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine, J. Pharm. Biomed. Anal., 21, 641, 10.1016/S0731-7085(99)00167-3
Wang, 2004, The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus), Seizure, 13, 574, 10.1016/j.seizure.2004.01.007
Easterling, 1988, Plasma pharmacokinetics of topiramate, a new anticonvulsants in humans, Epilepsia, 29, 662
Mimrod, 2005, A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy, Epilepsia, 46, 1046, 10.1111/j.1528-1167.2005.06805.x
Rosenfeld, 1999, A study of topiramate pharmacokinetics and tolerability in children with epilepsy, Pediatr. Neurol., 20, 339, 10.1016/S0887-8994(99)00011-9
Riffitts, 1999, A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood, J. Pharm. Biomed. Anal., 19, 363, 10.1016/S0731-7085(98)00137-X
Mozayani, 1999, Distribution of topiramate in a medical examiner's case, J. Anal. Toxicol., 23, 556, 10.1093/jat/23.6.556
Bahrami, 2004, Sensitive analytical method for Topiramate in human serum by HPLC with pre-column fluorescent derivatization and its application in human pharmacokinetic studies, J. Chromatogr. B, 813, 175, 10.1016/j.jchromb.2004.09.054
Britzi, 2003, Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay, Ther. Drug Monit., 25, 314, 10.1097/00007691-200306000-00012
Contin, 2001, Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma, J. Chromatogr. B, 761, 133, 10.1016/S0378-4347(01)00302-4
Christensen, 2002, Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: Validation and comparison with fluorescence-polarization immunoassay, Ther. Drug Monit., 24, 658, 10.1097/00007691-200210000-00013
Berry, 2000, Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay, Ther. Drug Monit., 22, 460, 10.1097/00007691-200008000-00016
Snozek, 2010, Comparison of a new serum topiramate immunoassay to fluorescence polarization immunoassay, Ther. Drug Monit., 32, 107, 10.1097/FTD.0b013e3181c4cebb
Rey, 1992, Vigabatrin. Clinical pharmacokinetics, Clin. Pharmacokinet., 23, 267, 10.2165/00003088-199223040-00003
Schechter, 1989, Clinical pharmacology of vigabatrin, Br. J. Clin. Pharmacol., 27, S19, 10.1111/j.1365-2125.1989.tb03456.x
Durham, 1993, Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers, Drug Metab. Dispos., 21, 480
Guillonneau, 1997, Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure, Br. J. Clin. Pharmacol., 44, 183, 10.1046/j.1365-2125.1997.00636.x
Chang, 2003, Determination of vigabatrin by capillary electrophoresis with laser-induced fluorescence detection, J. Chromatogr. B, 794, 17, 10.1016/S1570-0232(03)00396-9
Erturk, 2001, Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with fluorescence detection, J. Chromatogr. B, 760, 207, 10.1016/S0378-4347(01)00268-7
Buchanan, 1996, Single- and multiple-dose pharmacokinetics of zonisamide, Epilepsia, 37, 172
Ijiri, 2004, Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis, Epilepsia, 45, 924, 10.1111/j.0013-9580.2004.30603.x
Berent, 1987, Zonisamide (CI-912) and cognition:Results from preliminary study, Epilepsia, 28, 61, 10.1111/j.1528-1157.1987.tb03624.x
Glauser, 2000, Controversies in blood-level monitoring: re-examining its role in the treatment of epilepsy, Epilepsia, 41, S6, 10.1111/j.1528-1157.2000.tb02950.x
Juenke, 2006, Drug monitoring and toxicology: A procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV, J. Anal. Toxicol., 30, 27, 10.1093/jat/30.1.27
Nakamura, 2001, High-performance liquid chromatographic assay of zonisamide in human plasma using a non-porous silica column, J. Chromatogr. B, 755, 337, 10.1016/S0378-4347(01)00062-7
Subramanian, 2008, High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry, Ther. Drug Monit., 30, 347, 10.1097/FTD.0b013e3181678ecb